Prime Highlight:
- PrimeGen US and DT Cloud Star Acquisition have agreed to merge, creating a company valued at about $1.5 billion to strengthen PrimeGen’s regenerative medicine ambitions.
- The deal is expected to improve access to public market funding, supporting clinical development and future commercialisation of stem cell therapies.
Key Facts:
- The merged company plans to operate under the PrimeGen US name and list on Nasdaq under a new ticker, subject to regulatory and exchange approvals.
- The transaction is expected to close in the second half of 2026, pending shareholder approval, regulatory clearances, and other standard closing conditions.
Background:
PrimeGen US and DT Cloud Star Acquisition have agreed to merge, creating a company valued at about $1.5 billion. The deal will help PrimeGen US strengthen its position in regenerative medicine and access public market funding.
Under the agreement, the transaction will help advance PrimeGen US’s stem cell research and development. The capital raised through the merger is expected to support upcoming clinical studies, regulatory work and potential future commercialisation of its therapies.
The proposed deal remains subject to several conditions. These include approval from shareholders of both companies, required regulatory clearances and the fulfillment of minimum cash and redemption requirements. The companies said the transaction must also comply with standard closing conditions, including those under the Hart-Scott-Rodino Antitrust Improvements Act, where applicable.
Once completed, the combined company plans to operate under the PrimeGen US name or a successor entity. It also expects to list its shares on the Nasdaq exchange under a new ticker symbol, subject to regulatory and exchange approvals.
The companies said they expect the transaction to close in the second half of 2026. However, they noted that there is no guarantee the deal will be completed or that it will close within the expected timeframe.
PrimeGen US focuses on regenerative medicine and builds on nearly 20 years of stem cell research. The company is developing triple-activated mesenchymal stem cells to treat acute liver injury and related serious illnesses.
In December 2025, PrimeGen US completed a pre-investigational new drug meeting with the US Food and Drug Administration for acute alcoholic hepatitis, a severe form of liver failure. The company is now preparing for a clinical trial, subject to regulatory approval.
Commenting on the deal, PrimeGen US co-chief executive officer and chairman Daniel Chiu said the transaction is expected to improve access to capital and resources, supporting the continued development of its stem cell and exosome programmes and expanding its presence in regenerative medicine.
